Skip to main content
PMC home page
Bulletin of the New York Academy of Medicine logoLink to Bulletin of the New York Academy of Medicine
. 1989 Sep;65(7):787–800.

AIDS in New York City: the role of intravenous drug users.

A Ron, D E Rogers
PMCID: PMC1807824  PMID: 2695203

Abstract

The key to the future of the HIV epidemic is the intravenous drug user. In New York City the future has arrived--intravenous drug use is now the predominant risk factor among new cases of AIDS. Our limited knowledge of most facets of drug abuse prevention and treatment and the emotional polarity and politicalization of the issues surrounding AIDS have made control of its spread among intravenous drug users very difficult. Clearly new research efforts are needed better to decide how to reduce the further spread of HIV infection among this group. But efforts to stop the spread cannot await these results. Intense and immediate efforts should focus on five areas for potential control of the spread of HIV infection among drug users: education, treatment on demand, expanding support services, providing sterile equipment, and readjustment of some of society's moral judgments that currently block action. Let us hope that in 10 years we do not look back and realize that we did too little too late while it was still possible to make a difference.

Full text

PDF
791

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chaisson R. E., Moss A. R., Onishi R., Osmond D., Carlson J. R. Human immunodeficiency virus infection in heterosexual intravenous drug users in San Francisco. Am J Public Health. 1987 Feb;77(2):169–172. doi: 10.2105/ajph.77.2.169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Des Jarlais D. C., Friedman S. R. HIV infection among intravenous drug users: epidemiology and risk reduction. AIDS. 1987 Jul;1(2):67–76. [PubMed] [Google Scholar]
  3. Des Jarlais D. C., Friedman S. R., Hopkins W. Risk reduction for the acquired immunodeficiency syndrome among intravenous drug users. Ann Intern Med. 1985 Nov;103(5):755–759. doi: 10.7326/0003-4819-103-5-755. [DOI] [PubMed] [Google Scholar]
  4. Dole V. P., Nyswander M. E. Heroin addiction--a metabolic disease. Arch Intern Med. 1967 Jul;120(1):19–24. [PubMed] [Google Scholar]
  5. Drucker E. AIDS and addiction in New York City. Am J Drug Alcohol Abuse. 1986;12(1-2):165–181. doi: 10.3109/00952998609083750. [DOI] [PubMed] [Google Scholar]
  6. Friedland G. H., Harris C., Butkus-Small C., Shine D., Moll B., Darrow W., Klein R. S. Intravenous drug abusers and the acquired immunodeficiency syndrome (AIDS). Demographic, drug use, and needle-sharing patterns. Arch Intern Med. 1985 Aug;145(8):1413–1417. [PubMed] [Google Scholar]
  7. Friedman S. R., Des Jarlais D. C., Sotheran J. L. AIDS health education for intravenous drug users. Health Educ Q. 1986 Winter;13(4):383–393. doi: 10.1177/109019818601300409. [DOI] [PubMed] [Google Scholar]
  8. Ginzburg H. M. Intravenous drug users and the acquired immune deficiency syndrome. Public Health Rep. 1984 Mar-Apr;99(2):206–212. [PMC free article] [PubMed] [Google Scholar]
  9. Hardy A. M., Rauch K., Echenberg D., Morgan W. M., Curran J. W. The economic impact of the first 10,000 cases of acquired immunodeficiency syndrome in the United States. JAMA. 1986 Jan 10;255(2):209–211. [PubMed] [Google Scholar]
  10. Hartnoll R., Lewis R., Mitcheson M., Bryer S. Estimating the prevalence of opioid dependence. Lancet. 1985 Jan 26;1(8422):203–205. doi: 10.1016/s0140-6736(85)92036-7. [DOI] [PubMed] [Google Scholar]
  11. Irwin C. E., Jr, Millstein S. G. Biopsychosocial correlates of risk-taking behaviors during adolescence. Can the physician intervene? J Adolesc Health Care. 1986 Nov;7(6 Suppl):82S–96S. [PubMed] [Google Scholar]
  12. Leventhal H., Cleary P. D. The smoking problem: a review of the research and theory in behavioral risk modification. Psychol Bull. 1980 Sep;88(2):370–405. doi: 10.1037/0033-2909.88.2.370. [DOI] [PubMed] [Google Scholar]
  13. Newman R. G. Methadone treatment. Defining and evaluating success. N Engl J Med. 1987 Aug 13;317(7):447–450. doi: 10.1056/NEJM198708133170710. [DOI] [PubMed] [Google Scholar]
  14. Newman R. G. The need to redefine "addiction". N Engl J Med. 1983 May 5;308(18):1096–1098. doi: 10.1056/NEJM198305053081811. [DOI] [PubMed] [Google Scholar]
  15. Robertson J. R., Bucknall A. B., Welsby P. D., Roberts J. J., Inglis J. M., Peutherer J. F., Brettle R. P. Epidemic of AIDS related virus (HTLV-III/LAV) infection among intravenous drug abusers. Br Med J (Clin Res Ed) 1986 Feb 22;292(6519):527–529. doi: 10.1136/bmj.292.6519.527. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Vaillant G. E. The natural history of narcotic drug addiction. Semin Psychiatry. 1970 Nov;2(4):486–498. [PubMed] [Google Scholar]
  17. Weinberg D. S., Murray H. W. Coping with AIDS. The special problems of New York City. N Engl J Med. 1987 Dec 3;317(23):1469–1473. doi: 10.1056/NEJM198712033172309. [DOI] [PubMed] [Google Scholar]

Articles from Bulletin of the New York Academy of Medicine are provided here courtesy of New York Academy of Medicine

RESOURCES